NRG-GY035 for PMMR, TP53 mutated advanced or recurrent endometrial cancer

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
Protocol NRG-GY035, A Randomized Phase III Trial of Carboplatin, Paclitaxel, and Pembrolizumab versus Carboplatin, Paclitaxel, and Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab and Bevacizumab in the Treatment of PMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer (NCT07198074)
Principal Investigator
Headshot of Angeles Alvarez Secord
Professor of Obstetrics and Gynecology
Protocol Number
IRB: PRO00119814
NCT: NCT07198074
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL